Navigation Links
Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
Date:6/14/2011

SAN DIEGO, June 14, 2011 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock. MP4OX is a novel oxygen therapeutic agent that is designed to provide rapid oxygen delivery to ischemic tissues.

"Based on results from the preclinical and Phase 2a studies, MP4OX has shown its potential in improving outcomes in bleeding trauma patients," said Karim Brohi, Professor of Trauma Sciences at the Royal London Hospital. "These studies have shown that MP4OX may increase the delivery of oxygen to the body and prevent organs from failing when a patient is experiencing hemorrhagic shock.  This trial initiation is a key phase in finding a treatment that can improve patient outcomes after major trauma."

The clinical trial is a multi-center, randomized, double-blind, controlled study that will enroll approximately 360 patients who have suffered hemorrhagic shock with lactic acidosis across approximately 50 trial sites in 15 countries. The primary objective of the study is to measure the proportion of patients discharged alive from the hospital, as well as a number of secondary endpoints including lactic acidosis resolution. The dosing regimen in this study will include an initial dose of 250 mL of MP4OX plus up to three replacement doses of 250 mL each, all within 12 hours following the initial dose.

"The initiation of this study is another important step in bringing MP4OX to patients with medical conditions that deprive tissue of necessary oxygen," said Brian O'Callaghan, President and CEO of Sangart. "We remain committed to developing medicines designed to enhance the delivery of oxygen to tissues and organs that are oxygen-deprived, particularly in patients who experience an acute traumatic injury."

Acute traumatic injury, including both blunt and penetrating trauma is often associated with severe bleeding which can lead to hemorrhagic shock. During shock, inadequate perfusion of critical organs can lead to insufficient oxygenation of tissues, despite resuscitation, and can be detected by an increase in lactate levels.

About MP4Sangart's product platform is based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in the capillaries. Using a novel pegylation approach, Sangart produces the MP4 molecule designed at the optimal oxygen affinity, diffusion potential and molecular size to perfuse capillaries and target oxygen delivery to tissues specifically at risk of ischemia.

About TraumaTraumatic injuries, including both penetrating trauma injuries such as bullet and knife wounds and blunt trauma from car accidents and falls, cause the death of over 5 million people each year world-wide. Trauma is the leading cause of death in people under the age of 44. Despite optimal care, many patients treated for traumatic injuries suffer organ dysfunction and failure. Elevated lactate levels (lactic acidosis), which indicate hypoperfusion and anaerobic metabolism (oxygen deprivation) in tissues and organs in the body, represent metabolic failure and also cardiovascular, renal and hepatic dysfunction. Prolonged lactic acidosis correlates with worse outcomes and higher mortality.

About SangartSangart is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. Based on more than a decade of research, Sangart has refined the pegylation of human hemoglobin to create a molecule, MP4, with the ability to carry oxygen through the circulatory system to prevent and treat ischemia.

To learn more about Sangart, please visit the company's website at www.sangart.com.Media Contact:Marites Cristobal CoulterEdelman Public Relations

Office: 323-202-1424Marites.Cristobal@edelman.com

Cell: 415-819-2214
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangart Announces Closing of $50 Million Series G Financing
2. Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
3. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
4. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
7. Masimo Initiates Limited Market Release of E1, Single-Patient-Use Ear Sensor for Pulse Oximetry Monitoring
8. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
9. American Regent Initiates Nationwide Voluntary Recall of Sterile Water for Injection, USP, 50 mL Single Dose Vial Due to Particulate Matter
10. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
11. BAETA Corp Initiates Clinical Trial at NYU School of Medicine to Measure Efficacy of Pain Recording Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... CITY, Calif. , Dec. 9, 2016  Nevro ... device company that is providing innovative evidence-based solutions for ... Scientific (NYSE: BSX ) has filed a ... United States District Court for the District of ... Boston Scientific,s patents covering technology related to stimulation leads, ...
(Date:12/9/2016)... -- MSD, a nationally recognized supplier of technology enabled ... health care facilities, announced today that it has completed ... a privately held national distributor of medical supplies and ... segments. We would like to welcome First Choice to ... will deliver significant and immediate value to MSD,s customers ...
(Date:12/9/2016)... LONDON , December 9, 2016 ... ICD, Subcutaneous ICD, Single-Chamber ICD, Dual-Chamber ICD, Cardiac ... External Defibrillators, Wearable Cardioverter Defibrillators The ... grow at a CAGR of 5.3% from 2016-2020 ... is expected to grow at a CAGR of ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The American ... audiologists—to remain a critical part of public access to hearing aid technology. , ... announced this week that, starting immediately, it would no longer enforce the ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... ... December 09, 2016 , ... Cellairis is a worldwide mobile device and ... iPhone , iPad and Samsung Galaxy devices with premium parts and accessories. ... to maximize convenience and accessibility for customers. While customers do their shopping, Cellairis can ...
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman Company is a ... As a means of expanding capabilities Flottman has added a G&K Vijuk TTM ... professional inserts (PIs) and patient package inserts (PPIs) that will marry with all ...
(Date:12/9/2016)... PITTSBURGH, PA (PRWEB) , ... December 09, 2016 , ... ... Miami, Fla. "I used this old family recipe, which is meant to relieve gout ... and it gave me a 12-hour energy boost every time. It relieved what VA ...
Breaking Medicine News(10 mins):